Apixaban Use in CKD Stage 4

Introduction to Apixaban in CKD Stage 4

Apixaban can be used with caution in CKD stage 4 patients (CrCl 15-29 mL/min) at a reduced dose of 2.5 mg twice daily, with evidence suggesting it may have a better safety profile than warfarin in this population 1, 2

For patients with CKD stage 4 (CrCl 15-29 mL/min), apixaban should be prescribed at a reduced dose of 2.5 mg twice daily 2
Dose reduction is also required if the patient has at least two of the following characteristics, including body weight ≤60 kg 2

The 2024 KDIGO guidelines recommend non-vitamin K antagonist oral anticoagulants (NOACs) over vitamin K antagonists (e.g., warfarin) for thromboprophylaxis in atrial fibrillation patients with CKD G1-G4 (1C recommendation) 1, 3
Apixaban has the lowest renal clearance (27%) among NOACs, making it potentially more suitable for patients with impaired renal function 4, 5

Regular monitoring of renal function is essential in CKD patients on NOACs, with more frequent evaluation recommended for those with CrCl <60 mL/min 4
For patients with CrCl <60 mL/min, renal function should be evaluated at least every 6-12 months 4
Concomitant use of medications that may increase bleeding risk should be carefully evaluated 6

Carefully assess stroke and bleeding risks using validated tools (CHA₂DS₂-VASc and HAS-BLED) 1, 3
Consider apixaban 2.5 mg twice daily for CKD stage 4 patients requiring anticoagulation 2
Monitor renal function at least every 3 months in CKD stage 4 patients 4
Reassess the need for continued anticoagulation periodically, weighing benefits against risks 7, 8
For patients transitioning to CKD stage 5 or dialysis, a careful reassessment of anticoagulation strategy is warranted 8, 5